Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
IAM Catalyst Timeline
Dated clinical, regulatory and corporate events for Iambic Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How IAM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every IAM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in IAM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in IAM for Q3 2026. | ||||
Ownership Trends
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How IAM ranks across every disease it competes in
IAM News
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
Iambic reported strong third quarter results, highlighting the launch of Enchant v3 and collaborations with Bayer and AbbVie. The company achieved a milestone payment from Takeda and presented promising data for IAM1363 at ESMO 2026. With a cash position of approximately $455 million, Iambic is well-positioned for future developments.
Read more →Iambic to participate in Jefferies Global Healthcare Conference
Iambic's CEO, Tom Miller, will participate in the Jefferies Global Healthcare Conference from November 16-19, 2026. He will join a panel discussing AI in drug discovery on November 18. The conference is a significant event in Europe for healthcare leaders. Iambic aims to enhance drug development through its AI-driven platform.
Read more →Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Iambic Therapeutics presented updated clinical data for IAM1363 at ESMO 2026, showing durable responses and a favorable tolerability profile in heavily pretreated patients with HER2-driven cancers. The Phase 1/1b study demonstrated low rates of serious adverse events and notable intracranial responses. Over half of the participants treated with IAM1363 remain on study, indicating promising efficacy.
Read more →Iambic Announces Pricing of Initial Public Offering
Iambic Therapeutics announced the pricing of its initial public offering at $16.00 per share, aiming to raise $150.0 million. The IPO includes 9,375,000 shares, with an additional option for underwriters to purchase more. Trading is set to commence on October 15, 2026, on the Nasdaq under the ticker 'IAM'.
Read more →Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate
Iambic Therapeutics has submitted an IND application for IAM217, a KIF18A inhibitor, to the FDA for a Phase 1/2 trial. The drug demonstrated about 90% tumor regression in preclinical models and targets triple-negative breast cancer and other solid tumors. This marks Iambic's second candidate entering clinical trials, following IAM1363.
Read more →Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development
Iambic launched Enchant v3, an advanced multimodal transformer model designed to enhance drug discovery and development. With 41 billion parameters and trained on diverse biomedical data, it aims to optimize decision-making processes. The new model builds on previous versions, demonstrating improved predictive capabilities and supporting the company's mission to develop better medicines.
Read more →Bayer and Iambic collaborate to advance drug discovery with AI
Bayer and Iambic Therapeutics announced a collaboration to enhance drug discovery using Iambic's AI platform. This partnership focuses on small molecule discovery and aims to identify novel drug entry points. By leveraging AI, the collaboration seeks to accelerate drug development timelines and strengthen Bayer's research portfolio.
Read more →Iambic Named to CNBC Disruptor 50 for Second Consecutive Year
Iambic has been recognized as a CNBC Disruptor 50 for the second consecutive year, highlighting its innovative approach in drug discovery. The company has formed significant partnerships, including a $1.7 billion deal with Takeda. Iambic's AI-driven platform has shown promising results, including rapid clinical advancements for its drug candidate IAM1363.
Read more →Iambic to participate in upcoming investor conferences
Iambic announced its participation in several upcoming investor conferences, including the Bank of America Healthcare Conference and the Jefferies Global Healthcare Conference. Key executives, including CEO Tom Miller and CFO Michael Secora, will engage with investors and present the company's advancements. Iambic focuses on developing novel medicines through its AI-driven platform.
Read more →